336 related articles for article (PubMed ID: 26607741)
41. Prevalence of CD8
Blessin NC; Spriestersbach P; Li W; Mandelkow T; Dum D; Simon R; Hube-Magg C; Lutz F; Viehweger F; Lennartz M; Fraune C; Nickelsen V; Fehrle W; Göbel C; Weidemann S; Clauditz T; Lebok P; Möller K; Steurer S; Izbicki JR; Sauter G; Minner S; Jacobsen F; Luebke AM; Büscheck F; Höflmayer D; Wilczak W; Burandt E; Hinsch A
Cell Oncol (Dordr); 2020 Jun; 43(3):421-430. PubMed ID: 32141029
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of innate and adaptive immunity in colorectal cancer.
Grizzi F; Bianchi P; Malesci A; Laghi L
World J Gastroenterol; 2013 Jan; 19(2):174-84. PubMed ID: 23345940
[TBL] [Abstract][Full Text] [Related]
43. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
44. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
Peske JD; Woods AB; Engelhard VH
Adv Cancer Res; 2015; 128():263-307. PubMed ID: 26216636
[TBL] [Abstract][Full Text] [Related]
45. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
46. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
Chouaib S
Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
[TBL] [Abstract][Full Text] [Related]
47. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
48. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
50. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S
Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468
[TBL] [Abstract][Full Text] [Related]
51. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment.
Xu W; Liu WR; Xu Y; Tian X; Anwaier A; Su JQ; Zhu WK; Shi GH; Wei GM; Huang YP; Qu YY; Zhang HL; Ye DW
Int J Biol Sci; 2021; 17(9):2205-2222. PubMed ID: 34239350
[No Abstract] [Full Text] [Related]
52. Overview of Basic Immunology and Clinical Application.
Stephen B; Hajjar J
Adv Exp Med Biol; 2020; 1244():1-36. PubMed ID: 32301008
[TBL] [Abstract][Full Text] [Related]
53. Macrophage-Mediated Subversion of Anti-Tumour Immunity.
Quaranta V; Schmid MC
Cells; 2019 Jul; 8(7):. PubMed ID: 31331034
[TBL] [Abstract][Full Text] [Related]
54. Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.
Yang Y; Yang X; Wang Y; Xu J; Shen H; Gou H; Qin X; Jiang G
Front Immunol; 2022; 13():811007. PubMed ID: 35222387
[TBL] [Abstract][Full Text] [Related]
55. Immune infiltration in human cancer: prognostic significance and disease control.
Fridman WH; Galon J; Dieu-Nosjean MC; Cremer I; Fisson S; Damotte D; Pagès F; Tartour E; Sautès-Fridman C
Curr Top Microbiol Immunol; 2011; 344():1-24. PubMed ID: 20512556
[TBL] [Abstract][Full Text] [Related]
56. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
[TBL] [Abstract][Full Text] [Related]
57. A study of the immune infiltrate and patient outcomes in esophageal cancer.
Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
[TBL] [Abstract][Full Text] [Related]
58. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
[TBL] [Abstract][Full Text] [Related]
59. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
Habanjar O; Bingula R; Decombat C; Diab-Assaf M; Caldefie-Chezet F; Delort L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835413
[TBL] [Abstract][Full Text] [Related]
60. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]